Combination immunotherapy benefits subset of patients with advanced prostate cancer
Results from a Phase II trial led by researchers at The University of Texas MD…
Browsing: mCRPC
Blood test can guide treatment for most aggressive prostate cancer
Scientists have developed a simple blood test that can show which men with the most…
ASCO GU 2019: Phase II Trial Shows Novel, Radiolabeled PSMA-Targeted Treatment Provides High Response Rates in Men With Metastatic Prostate Cancer
A single-arm, phase II trial in men with PSMA-positive metastatic, castration-resistant prostate cancer (mCRPC) that…